SCHEMBL585467

SCHEMBL585467

CC(C)(C)OC(=O)N1C[C@H](C(C)(C)O[SiH2]C(C)(C)C)C[C@H]1COc1c(F)c(F)cc2c(=O)c(C(=O)OCc3ccccc3)cn(C3CC3)c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.40
STAT3 P40763 1/20 0.39
KDM4E B2RXH2 7/20 0.38
ALDH1A1 P00352 3/20 0.38
POLB P06746 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
LMNA P02545 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HPGD P15428 3/20 0.35
KCNH2 Q12809 3/20 0.35
ADRB2 P07550 1/20 0.35
ABCB1 P08183 1/20 0.34
PRKD3 O94806 1/20 0.34
ALOX15 P16050 1/20 0.34
OPRM1 P35372 1/20 0.34
CLK2 P49760 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
TOP2A P11388 2/20 0.34
TOP2B Q02880 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2847606 1.00 GSK3B (0.40) GSK3BSTAT3KDM4EALDH1A1POLB
SCHEMBL595859 1.00 GSK3B (0.40) GSK3BSTAT3KDM4EALDH1A1POLB
SCHEMBL3054228 0.91 ADRB2 (0.43) GSK3BSTAT3KDM4EALDH1A1POLB
SCHEMBL584820 0.91 ADRB2 (0.43) GSK3BSTAT3KDM4EALDH1A1POLB
SCHEMBL584191 0.91 ADRB2 (0.43) GSK3BSTAT3KDM4EALDH1A1POLB
SCHEMBL584331 0.90 KCNH2 (0.43) GSK3BKDM4EALDH1A1POLBTDP1
SCHEMBL2844980 0.90 KCNH2 (0.43) GSK3BKDM4EALDH1A1POLBTDP1
SCHEMBL584992 0.90 KCNH2 (0.43) GSK3BKDM4EALDH1A1POLBTDP1
SCHEMBL2847619 0.87 STAT3 (0.42) GSK3BSTAT3KDM4EALDH1A1POLB
SCHEMBL2841900 0.87 STAT3 (0.42) GSK3BSTAT3KDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222302-A1 Novel Antibacterial Compounds ACTELION PHARMACEUTICALS LTD (CH) 2010-09-02 US claimed
EP-2102217-B1 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS ACTELION PHARMACEUTICALS LTD (CH) 2012-02-15 EP disclosed
US-8039466-B2 5-hydroxymethyl-oxazolidin-2-one antibacterials ACTELION PHARMACEUTICAL LTD. (CH) 2011-10-18 US disclosed
EP-2256120-A1 Oxazolidinone-quinolone hybrids as antibacterial compounds Actelion Pharmaceuticals Ltd. (CH) 2010-12-01 EP disclosed
US-20100222302-A1 Novel Antibacterial Compounds ACTELION PHARMACEUTICALS LTD (CH) 2010-09-02 US disclosed
US-20100069376-A1 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS ACTELION PHARMACEUTICALS, LTD. (CH) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069376-A1 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS OGFOD1, ODC1, OXGR1 GSK3B 3710/4885STAT3 4566/4885KDM4E 1273/4885
US-20100222302-A1 Novel Antibacterial Compounds ODC1, AOC1, OGFOD1 GSK3B 4330/4885STAT3 4545/4885KDM4E 2548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.